Management Strategies for Pediatric Patients with Adrenal Insufficiency
Overview
This report reviews the challenges and advances in managing pediatric adrenal insufficiency (AI), highlighting three clinical cases with distinct etiologies. It emphasizes personalized glucocorticoid therapy, novel treatment modalities, and the importance of early diagnosis and tailored management to optimize outcomes.
Background
Adrenal insufficiency in children requires careful management to prevent adrenal crises, control androgen excess in congenital adrenal hyperplasia (CAH), and support normal growth and quality of life. Traditional glucocorticoid therapies do not replicate physiological cortisol rhythms, prompting development of new pharmacological approaches. These include modified-release hydrocortisone formulations and adjunctive therapies to better mimic natural cortisol secretion and reduce androgen effects. Genetic and hormonal testing alongside imaging are essential for diagnosis and guiding treatment.
Data Highlights
Case
Age at Presentation
Diagnosis
Key Hormonal Findings
Treatment
1
3 weeks
Classic CAH (21-hydroxylase deficiency)
Hyponatremia (Na 117 mEq/L), Hyperkalemia (K 7.1 mEq/L), High ACTH (78.14 pg/mL), Low cortisol (3.30 mcg/dL), Elevated 17OHP (>44 ng/mL), Androstenedione (10 ng/mL), Testosterone (7.44 ng/dL), High renin (>550 μIU/mL)
Classic CAH presents early with salt-wasting crisis, ambiguous genitalia, and requires prompt glucocorticoid and mineralocorticoid replacement.
Nonclassic CAH may present later with premature pubarche, androgen excess, and menstrual irregularities despite treatment.
Central adrenal insufficiency can be associated with pituitary abnormalities and requires hydrocortisone and thyroid hormone replacement.
Standard glucocorticoid therapies do not replicate physiological cortisol rhythms, motivating development of modified-release formulations.
Genetic testing confirms diagnosis and guides personalized treatment strategies in pediatric AI.
Clinical Implications
Early recognition and diagnosis of AI subtypes are critical to prevent life-threatening crises and optimize growth and development. Personalized glucocorticoid regimens, including novel modified-release formulations, may improve hormonal control and quality of life. Multidisciplinary management including genetic, hormonal, and imaging assessments is essential for tailored therapy.
Conclusion
Management of pediatric adrenal insufficiency requires individualized approaches based on etiology and clinical presentation. Advances in pharmacotherapy and diagnostic techniques hold promise for improved outcomes in affected children and adolescents.
References
Management Strategies for Pediatric Patients with Adrenal Insufficiency -- Clinical Report
